PAREXEL International (PRXL) Getting Favorable News Coverage, Analysis Finds

News headlines about PAREXEL International (NASDAQ:PRXL) have been trending positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAREXEL International earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.4858702429869 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered PAREXEL International from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. BidaskClub lowered PAREXEL International from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $76.81.

PAREXEL International (NASDAQ:PRXL) last posted its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.08. The firm had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. PAREXEL International had a net margin of 4.62% and a return on equity of 19.95%. During the same period in the prior year, the company posted $0.94 earnings per share.

COPYRIGHT VIOLATION WARNING: “PAREXEL International (PRXL) Getting Favorable News Coverage, Analysis Finds” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Insider Buying and Selling by Quarter for PAREXEL International (NASDAQ:PRXL)

What are top analysts saying about PAREXEL International Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PAREXEL International Co. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit